Annovis Bio Inc
ANVS
Company Profile
Business description
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.
Contact
101 Lindenwood Drive
Suite 225
MalvernPA19355
USAT: +1 484 875-3192
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
6
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,065.10 | 130.40 | -1.59% |
| CAC 40 | 7,916.08 | 74.03 | -0.93% |
| DAX 40 | 22,461.52 | 217.22 | -0.96% |
| Dow JONES (US) | 41,583.90 | 715.80 | -1.69% |
| FTSE 100 | 8,658.85 | 7.27 | -0.08% |
| HKSE | 23,097.79 | 328.81 | -1.40% |
| NASDAQ | 17,322.99 | 481.04 | -2.70% |
| Nikkei 225 | 35,691.52 | 1,428.81 | -3.85% |
| NZX 50 Index | 12,266.35 | 21.11 | -0.17% |
| S&P 500 | 5,580.94 | 112.37 | -1.97% |
| S&P/ASX 200 | 7,854.60 | 127.40 | -1.60% |
| SSE Composite Index | 3,325.41 | 25.90 | -0.77% |